Tag:

Novartis

Latest Headlines

Latest Headlines

Fast-growing Celgene snaps up Merck's abandoned NJ campus

Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old campus in Summit, NJ, adding the sprawling 1.3-million-square-foot complex to its already growing operations in the city.

Novartis launches navigation app for visually disabled on Apple Watch

Novartis launched its ViaOpta navigation app for the visually impaired on the Apple Watch, making it the first app of its kind to run on a smartwatch. It's also available on Android Wear.

Stormy Australia hearings on transfer pricing by drug firms invoke Sergeant Schultz

Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.

Feds demand $3.4B in damages, fines in Novartis kickback case

Kickback allegations against Novartis just got scarier. After years of investigating the Swiss drugmaker, the Justice Department and 11 states are demanding almost $3.4 billion in damages and fines in a False Claims Act lawsuit nearing trial.

Feds want Novartis to cough up $3.4B in damages, fines in kickback case

Kickback allegations against Novartis just got scarier. After years of investigating the Swiss drugmaker, the Justice Department and 11 states are demanding almost $3.4 billion in damages and fines in a False Claims Act lawsuit nearing trial.

Novartis tests performance pricing for much-anticipated Entresto launch

Novartis has big plans for its much-anticipated heart failure remedy Entresto. The Swiss drugmaker figures it can parlay impressive trial data on the drug into its biggest launch in years--perhaps ever.

No artful tax dodging here, drug firms tell Australia transfer-price inquiry

We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.

Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug

Novartis snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal.

Novartis puts Cosentyx on track for $4B-plus with new psoriatic arthritis data

With competitors hot on its trail in the next-gen psoriasis drug market, Novartis is looking to build out the list of indications for its up-and-comer, Cosentyx. And with an eye on that goal, it just scored a boost in psoriatic arthritis, one of two label expansions it's filed for with the FDA.

India's Gujarat state drugmakers speed up biosimilar race

Drug companies in India's leading industrial state of Gujarat, the base of Prime Minister Narendra Modi, are stepping up efforts to crack the domestic market for biosimilars as well as abroad, Business Standard reports.